CYduct Diagnostics, Inc. Announces the Appointment of Anthony L.G., PLLC as Corporate and Securities Counsel
Back to Newsroom
Mentioned in this Article

CYduct Diagnostics, Inc. Announces the Appointment of Anthony L.G., PLLC as Corporate and Securities Counsel

Monday, November 15, 2021 10:00 AM
Share this article now
Company Update
CYduct Diagnostics, Inc.

WESTPORT, CT / ACCESSWIRE / November 15, 2021 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct") is pleased to announce the retaining of Ms. Laura Anthony and the firm Anthony L.G., PLLC.

Commenting on the appointment of Anthony L.G., PLLC, Dominick Gatto, CYduct's Chief Executive Officer stated, "We look forward to a successful relationship with a legal firm that can only be provided by a corporate and securities law firm that knows our business operations from the ground up."

Mr. Gatto continued, "I am pleased to welcome Laura Anthony and her team and look forward to their vast experience in working with small to mid-size publicly traded companies, as we work to realize the full potential of our company and enhance our value to our customers and shareholders. Our company is at the stage where innovative and strategic legal plans are needed to move the company successfully forward, and are confident in the team at Anthony L.G., PLLC."

About CYduct Diagnostics, Inc.:

CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products will be available on the Company's website at:

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the Company, are forward-looking statements that involve significant risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The inability to raise additional capital, and technical complications in research, product development and validation, among other things, could prevent the implementation of strategically significant plan(s) outlined above. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

CYduct Diagnostics, Inc.
Investor Relations
(888) 545-9112

SOURCE: CYduct Diagnostics, Inc.

Back to Newsroom
Copyright 2022 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions